Combination of recombinant human endostatin and GP in the treatment of advanced non-small cell lung cancer / 中国基层医药

ABSTRACT

Objective To observe the efficacy and safety of recombinant human endostatin injection (en-dostar) combined with GP(gemcitabine plus cisplatin)regimen in patients with advanced non- small cell lung cancer (NSCLC). Methods Thirty seven histologically confirmed advanced NSCLC patients were enrolled in the group. The patients were administered with endostar 15 mg from day 1 to 14,gemcitabine 1 000 mg/m2 day 1 and 8,cisplatin 80 mg/m2 on days devided into 1 - 3, repeated 21 days. Each patient should complete two cycles. Results 37 patients were valuable for response. One patient achieved complete response(CR), 15 partial response(PR), 14 stable disease (SD) ,and 7 were found to have disease progression(PD). The total response rate was 43.2% ,median TIP was 5.2 months. The main toxicities was leukopenia. There was no treatment-related death in this series. Conclusion En-dostar combined GP regimen was effective and safe in treatment of advanced NSCLC.